Tocilizumab reduces the unmanageable inflammatory reaction of a patient with Aicardi-Goutières syndrome type 7 during treatment with ruxolitinib

MLA

Wei Wang, et al. “Tocilizumab Reduces the Unmanageable Inflammatory Reaction of a Patient with Aicardi-Goutières Syndrome Type 7 during Treatment with Ruxolitinib.” Pediatric Rheumatology Online Journal, vol. 21, no. 1, Oct. 2023, pp. 1–6. EBSCOhost, https://doi.org/10.1186/s12969-023-00899-4.

APA

Wei Wang, Siming Peng, Sihao Gao, Meiying Quan, Lijuan Gou, Changyan Wang, Zhixing Sun, Zhuo Li, Dongmei Lian, & Hongmei Song. (2023). Tocilizumab reduces the unmanageable inflammatory reaction of a patient with Aicardi-Goutières syndrome type 7 during treatment with ruxolitinib. Pediatric Rheumatology Online Journal, 21(1), 1–6. https://doi.org/10.1186/s12969-023-00899-4

Chicago

Wei Wang, Siming Peng, Sihao Gao, Meiying Quan, Lijuan Gou, Changyan Wang, Zhixing Sun, Zhuo Li, Dongmei Lian, and Hongmei Song. 2023. “Tocilizumab Reduces the Unmanageable Inflammatory Reaction of a Patient with Aicardi-Goutières Syndrome Type 7 during Treatment with Ruxolitinib.” Pediatric Rheumatology Online Journal 21 (1): 1–6. doi:10.1186/s12969-023-00899-4.